Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

MLA

Orkin, Chloe, et al. “Safety and Efficacy of Doravirine as First-Line Therapy in Adults with HIV-1: Week 192 Results from the Open-Label Extensions of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Trials.” The Lancet HIV, vol. 11, no. 2, Feb. 2024, pp. e75–85. EBSCOhost, https://doi.org/10.1016/S2352-3018(23)00258-8.

APA

Orkin, C., Molina, J.-M., Cahn, P., Lombaard, J., Supparatpinyo, K., Kumar, S., Campbell, H., Wan, H., Teal, V., Jin Xu, Z., Asante-Appiah, E., Sklar, P., Teppler, H., Lahoulou, R., Martins, M. D., Cahn, P. E., Lopardo, G. D., Porteiro, N., Bloch, M. T., … Inciarte Portillo, A. (2024). Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. The Lancet HIV, 11(2), e75–e85. https://doi.org/10.1016/S2352-3018(23)00258-8

Chicago

Orkin, Chloe, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, et al. 2024. “Safety and Efficacy of Doravirine as First-Line Therapy in Adults with HIV-1: Week 192 Results from the Open-Label Extensions of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Trials.” The Lancet HIV 11 (2): e75–85. doi:10.1016/S2352-3018(23)00258-8.